Log in or register to see all Alerts
New HTA Decisions in England
September 2020
Drug name
POLIVY® (polatuzumab vedotin)
Decision date
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Polatuzumab vedotin with rituximab and bendamustine is recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B‑cell lymphoma in adults who cannot have a haematopoietic stem cell transplant.
Decision Detail
It is recommended only if the company provides polatuzumab vedotin according to the commercial arrangement (simple discount patient access scheme).
Clinical evidence came from trial GO29365, a multicentre, randomised, open-label trial of polatuzumab vedotin with rituximab and bendamustine, compared with rituximab with bendamustine alone, in patients with relapsed or refractory disease. The committee concluded that polatuzumab vedotin is a promising new treatment and that the evidence from the trial to date suggests that it extends both progression-free survival and overall survival. The committee noted that the probabilistic and deterministic ICERs from the company's standard parametric model and the ERG's standard parametric analyses (£35,663 to £48,839 per QALY gained) were within the range normally considered a cost-effective use of NHS resources for life-extending treatments at the end of life. Therefore, polatuzumab vedotin plus rituximab and bendamustine is recommended.